| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve Stenosis | 96 | 2023 | 2002 | 9.840 |
Why?
|
| Heart Valve Prosthesis | 65 | 2023 | 1466 | 8.460 |
Why?
|
| Angioplasty, Balloon, Coronary | 187 | 2018 | 1730 | 7.680 |
Why?
|
| Aortic Valve | 76 | 2023 | 1950 | 7.400 |
Why?
|
| Heart Valve Prosthesis Implantation | 51 | 2023 | 1547 | 5.760 |
Why?
|
| Stents | 198 | 2020 | 3162 | 5.740 |
Why?
|
| Coronary Restenosis | 79 | 2021 | 396 | 4.570 |
Why?
|
| Drug-Eluting Stents | 62 | 2021 | 679 | 4.540 |
Why?
|
| Bioprosthesis | 27 | 2022 | 591 | 3.780 |
Why?
|
| Coronary Angiography | 225 | 2020 | 4451 | 3.680 |
Why?
|
| Prosthesis Design | 82 | 2023 | 2105 | 3.310 |
Why?
|
| Coronary Disease | 163 | 2012 | 5913 | 3.150 |
Why?
|
| Coronary Stenosis | 47 | 2019 | 793 | 3.040 |
Why?
|
| Sirolimus | 48 | 2019 | 1532 | 2.670 |
Why?
|
| Coronary Artery Disease | 104 | 2022 | 6363 | 2.660 |
Why?
|
| Atherectomy, Coronary | 51 | 2019 | 142 | 2.230 |
Why?
|
| Graft Occlusion, Vascular | 38 | 2016 | 537 | 2.010 |
Why?
|
| Aortic Valve Insufficiency | 14 | 2023 | 578 | 1.970 |
Why?
|
| Ultrasonography, Interventional | 94 | 2021 | 1487 | 1.890 |
Why?
|
| Paclitaxel | 36 | 2019 | 1731 | 1.810 |
Why?
|
| Cardiovascular Agents | 24 | 2020 | 839 | 1.660 |
Why?
|
| Absorbable Implants | 17 | 2021 | 338 | 1.570 |
Why?
|
| Treatment Outcome | 287 | 2023 | 64242 | 1.560 |
Why?
|
| Coronary Vessels | 86 | 2020 | 3072 | 1.520 |
Why?
|
| Angioplasty, Balloon | 23 | 2019 | 588 | 1.520 |
Why?
|
| Coronary Artery Bypass | 35 | 2019 | 2187 | 1.420 |
Why?
|
| Postoperative Complications | 69 | 2021 | 15532 | 1.370 |
Why?
|
| Intra-Aortic Balloon Pumping | 11 | 2019 | 223 | 1.350 |
Why?
|
| Cardiology | 14 | 2023 | 1667 | 1.250 |
Why?
|
| Coronary Occlusion | 5 | 2019 | 303 | 1.250 |
Why?
|
| Femoral Artery | 13 | 2020 | 824 | 1.190 |
Why?
|
| Saphenous Vein | 28 | 2018 | 517 | 1.180 |
Why?
|
| Coronary Thrombosis | 22 | 2020 | 440 | 1.170 |
Why?
|
| Prosthesis Failure | 15 | 2022 | 1197 | 1.100 |
Why?
|
| Myocardial Revascularization | 22 | 2019 | 792 | 1.060 |
Why?
|
| Aged | 329 | 2023 | 167889 | 1.040 |
Why?
|
| Coated Materials, Biocompatible | 12 | 2019 | 312 | 1.040 |
Why?
|
| Aged, 80 and over | 122 | 2023 | 58559 | 1.010 |
Why?
|
| Time Factors | 122 | 2022 | 39815 | 1.010 |
Why?
|
| Hemodynamics | 33 | 2022 | 4156 | 0.990 |
Why?
|
| Myocardial Infarction | 77 | 2022 | 11422 | 0.970 |
Why?
|
| Severity of Illness Index | 56 | 2020 | 15782 | 0.870 |
Why?
|
| Risk Factors | 138 | 2023 | 73716 | 0.860 |
Why?
|
| Male | 424 | 2023 | 358227 | 0.860 |
Why?
|
| Mitral Valve Insufficiency | 8 | 2019 | 1401 | 0.840 |
Why?
|
| Registries | 37 | 2022 | 8164 | 0.840 |
Why?
|
| Risk Assessment | 68 | 2021 | 23819 | 0.830 |
Why?
|
| Humans | 588 | 2023 | 757650 | 0.830 |
Why?
|
| Immunosuppressive Agents | 25 | 2019 | 4158 | 0.820 |
Why?
|
| Female | 414 | 2023 | 389985 | 0.810 |
Why?
|
| Stroke | 27 | 2023 | 9695 | 0.790 |
Why?
|
| Popliteal Artery | 7 | 2019 | 309 | 0.790 |
Why?
|
| Heart-Assist Devices | 14 | 2019 | 1279 | 0.780 |
Why?
|
| Angina, Unstable | 13 | 2010 | 887 | 0.780 |
Why?
|
| Prospective Studies | 128 | 2023 | 54108 | 0.770 |
Why?
|
| Thrombectomy | 7 | 2008 | 690 | 0.730 |
Why?
|
| Peripheral Arterial Disease | 11 | 2020 | 1246 | 0.710 |
Why?
|
| Geriatric Assessment | 9 | 2020 | 1402 | 0.700 |
Why?
|
| Blood Vessel Prosthesis Implantation | 26 | 2016 | 1426 | 0.700 |
Why?
|
| Vascular Patency | 20 | 2020 | 895 | 0.680 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2020 | 10135 | 0.670 |
Why?
|
| Intracranial Embolism | 4 | 2020 | 189 | 0.670 |
Why?
|
| Echocardiography | 26 | 2023 | 4962 | 0.650 |
Why?
|
| Follow-Up Studies | 120 | 2021 | 39018 | 0.640 |
Why?
|
| Filtration | 8 | 2010 | 227 | 0.600 |
Why?
|
| Heart Valve Diseases | 6 | 2019 | 1033 | 0.600 |
Why?
|
| Mitral Valve | 7 | 2021 | 1466 | 0.600 |
Why?
|
| Recurrence | 78 | 2019 | 8426 | 0.600 |
Why?
|
| Fibrinolytic Agents | 12 | 2008 | 2070 | 0.590 |
Why?
|
| Tunica Intima | 17 | 2014 | 459 | 0.590 |
Why?
|
| Platelet Aggregation Inhibitors | 27 | 2010 | 2746 | 0.590 |
Why?
|
| Brachytherapy | 13 | 2008 | 1224 | 0.590 |
Why?
|
| Recovery of Function | 20 | 2020 | 2970 | 0.590 |
Why?
|
| Alloys | 5 | 2017 | 110 | 0.560 |
Why?
|
| Middle Aged | 301 | 2020 | 219219 | 0.560 |
Why?
|
| Tissue Scaffolds | 8 | 2019 | 926 | 0.560 |
Why?
|
| United States | 93 | 2023 | 71907 | 0.550 |
Why?
|
| Bradycardia | 2 | 2008 | 299 | 0.550 |
Why?
|
| Carotid Stenosis | 8 | 2015 | 853 | 0.540 |
Why?
|
| Equipment Design | 36 | 2018 | 3501 | 0.530 |
Why?
|
| Multicenter Studies as Topic | 19 | 2023 | 1702 | 0.530 |
Why?
|
| Ventricular Function, Left | 13 | 2021 | 3858 | 0.510 |
Why?
|
| Ticlopidine | 10 | 2010 | 730 | 0.500 |
Why?
|
| Catheterization | 10 | 2018 | 1426 | 0.490 |
Why?
|
| Frail Elderly | 7 | 2020 | 752 | 0.480 |
Why?
|
| Echocardiography, Doppler | 5 | 2018 | 898 | 0.480 |
Why?
|
| Aortography | 1 | 2016 | 420 | 0.470 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 11 | 2006 | 577 | 0.470 |
Why?
|
| Metals | 12 | 2018 | 717 | 0.460 |
Why?
|
| Coronary Circulation | 23 | 2013 | 1561 | 0.460 |
Why?
|
| Remote Consultation | 3 | 2010 | 233 | 0.450 |
Why?
|
| Shock, Cardiogenic | 6 | 2019 | 707 | 0.430 |
Why?
|
| Mortality | 8 | 2021 | 2881 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 23 | 2019 | 6469 | 0.420 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 7 | 1998 | 23 | 0.410 |
Why?
|
| Hospital Mortality | 16 | 2019 | 5243 | 0.410 |
Why?
|
| Chromium Alloys | 5 | 2020 | 71 | 0.400 |
Why?
|
| Cause of Death | 17 | 2021 | 3668 | 0.390 |
Why?
|
| Clinical Trials as Topic | 29 | 2020 | 7982 | 0.380 |
Why?
|
| Embolism | 6 | 2010 | 401 | 0.380 |
Why?
|
| Single-Blind Method | 17 | 2020 | 1568 | 0.380 |
Why?
|
| Medicare | 13 | 2023 | 6717 | 0.380 |
Why?
|
| Congresses as Topic | 3 | 2010 | 799 | 0.380 |
Why?
|
| Thrombosis | 20 | 2017 | 2930 | 0.370 |
Why?
|
| Beta Particles | 6 | 2005 | 47 | 0.370 |
Why?
|
| Tyrosine | 5 | 2008 | 1432 | 0.360 |
Why?
|
| Intermittent Claudication | 3 | 2020 | 303 | 0.360 |
Why?
|
| Somatostatin | 3 | 2005 | 447 | 0.360 |
Why?
|
| Thrombolytic Therapy | 13 | 2005 | 2060 | 0.350 |
Why?
|
| Predictive Value of Tests | 32 | 2021 | 15209 | 0.350 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2019 | 2115 | 0.350 |
Why?
|
| Urokinase-Type Plasminogen Activator | 5 | 2002 | 325 | 0.350 |
Why?
|
| Angioplasty, Laser | 5 | 2001 | 18 | 0.350 |
Why?
|
| Constriction, Pathologic | 22 | 2019 | 1097 | 0.340 |
Why?
|
| Strontium Radioisotopes | 4 | 2005 | 18 | 0.340 |
Why?
|
| Catheterization, Peripheral | 5 | 2018 | 340 | 0.340 |
Why?
|
| Calcinosis | 13 | 2018 | 1467 | 0.340 |
Why?
|
| Endovascular Procedures | 7 | 2020 | 2139 | 0.330 |
Why?
|
| Patient Selection | 13 | 2017 | 4235 | 0.330 |
Why?
|
| Catheters | 2 | 2023 | 420 | 0.330 |
Why?
|
| Aorta | 3 | 2016 | 2037 | 0.330 |
Why?
|
| Endpoint Determination | 9 | 2021 | 590 | 0.330 |
Why?
|
| Angioplasty | 6 | 2015 | 354 | 0.320 |
Why?
|
| Propensity Score | 5 | 2020 | 1887 | 0.320 |
Why?
|
| Feasibility Studies | 24 | 2023 | 5195 | 0.320 |
Why?
|
| Iliac Artery | 3 | 2019 | 342 | 0.320 |
Why?
|
| Immunoglobulin Fab Fragments | 7 | 2004 | 444 | 0.310 |
Why?
|
| Endarterectomy, Carotid | 6 | 2015 | 549 | 0.310 |
Why?
|
| Renal Artery | 3 | 2021 | 351 | 0.310 |
Why?
|
| Yttrium Radioisotopes | 4 | 2005 | 107 | 0.310 |
Why?
|
| Drug Implants | 6 | 2019 | 230 | 0.310 |
Why?
|
| Hyperplasia | 13 | 2014 | 1153 | 0.310 |
Why?
|
| Stroke Volume | 10 | 2020 | 5460 | 0.310 |
Why?
|
| Quality of Life | 19 | 2023 | 13265 | 0.300 |
Why?
|
| Survival Rate | 26 | 2019 | 12685 | 0.300 |
Why?
|
| Tubulin Modulators | 3 | 2018 | 106 | 0.290 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2009 | 384 | 0.280 |
Why?
|
| Heparin | 8 | 2004 | 1632 | 0.280 |
Why?
|
| Stainless Steel | 4 | 2007 | 79 | 0.270 |
Why?
|
| Biomedical Research | 2 | 2012 | 3416 | 0.270 |
Why?
|
| Vibration | 1 | 2008 | 328 | 0.270 |
Why?
|
| Polyesters | 3 | 2017 | 370 | 0.270 |
Why?
|
| Anticoagulants | 10 | 2005 | 4776 | 0.270 |
Why?
|
| Angina Pectoris | 13 | 2015 | 958 | 0.270 |
Why?
|
| Organizational Objectives | 1 | 2008 | 426 | 0.270 |
Why?
|
| Oligopeptides | 2 | 2005 | 1185 | 0.270 |
Why?
|
| Specialty Boards | 1 | 2008 | 235 | 0.270 |
Why?
|
| Thallium Radioisotopes | 5 | 1994 | 138 | 0.260 |
Why?
|
| International Cooperation | 1 | 2012 | 1429 | 0.260 |
Why?
|
| Incidence | 30 | 2021 | 21217 | 0.260 |
Why?
|
| Certification | 2 | 2010 | 418 | 0.260 |
Why?
|
| Length of Stay | 7 | 2019 | 6384 | 0.240 |
Why?
|
| Diabetic Angiopathies | 8 | 2009 | 802 | 0.240 |
Why?
|
| Canada | 11 | 2020 | 2108 | 0.240 |
Why?
|
| Renal Artery Obstruction | 3 | 2021 | 219 | 0.240 |
Why?
|
| Japan | 8 | 2022 | 1364 | 0.240 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 700 | 0.230 |
Why?
|
| Atherectomy | 4 | 2016 | 40 | 0.230 |
Why?
|
| Electrocardiography | 11 | 2021 | 6363 | 0.230 |
Why?
|
| Dipyridamole | 5 | 1994 | 141 | 0.220 |
Why?
|
| Equipment Failure | 6 | 2014 | 577 | 0.220 |
Why?
|
| Hirudins | 1 | 2004 | 179 | 0.220 |
Why?
|
| Angiography | 8 | 2021 | 1600 | 0.210 |
Why?
|
| Hypertension, Renovascular | 2 | 2014 | 116 | 0.210 |
Why?
|
| Societies, Medical | 4 | 2011 | 3887 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 7 | 2009 | 1065 | 0.210 |
Why?
|
| Logistic Models | 20 | 2020 | 13222 | 0.200 |
Why?
|
| Bundle-Branch Block | 2 | 2021 | 278 | 0.200 |
Why?
|
| Retrospective Studies | 37 | 2021 | 79982 | 0.200 |
Why?
|
| Myocardial Ischemia | 6 | 2019 | 2108 | 0.190 |
Why?
|
| Evidence-Based Medicine | 5 | 2011 | 3667 | 0.190 |
Why?
|
| Laboratories | 3 | 2012 | 460 | 0.190 |
Why?
|
| Multivariate Analysis | 24 | 2019 | 12047 | 0.190 |
Why?
|
| Health Status | 5 | 2018 | 4066 | 0.190 |
Why?
|
| Cardiovascular Surgical Procedures | 3 | 2018 | 189 | 0.190 |
Why?
|
| Heart Defects, Congenital | 2 | 2021 | 4673 | 0.180 |
Why?
|
| France | 5 | 2020 | 499 | 0.180 |
Why?
|
| Double-Blind Method | 27 | 2014 | 12260 | 0.180 |
Why?
|
| Polymers | 9 | 2018 | 1613 | 0.180 |
Why?
|
| Europe | 9 | 2020 | 3415 | 0.180 |
Why?
|
| Quality of Health Care | 4 | 2019 | 4308 | 0.180 |
Why?
|
| Reoperation | 8 | 2018 | 4279 | 0.180 |
Why?
|
| Chi-Square Distribution | 10 | 2017 | 3415 | 0.170 |
Why?
|
| Cohort Studies | 25 | 2020 | 41198 | 0.170 |
Why?
|
| Embolic Protection Devices | 1 | 2020 | 41 | 0.170 |
Why?
|
| Prosthesis Implantation | 4 | 2017 | 590 | 0.170 |
Why?
|
| Denervation | 1 | 2021 | 263 | 0.170 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2009 | 621 | 0.170 |
Why?
|
| Combined Modality Therapy | 23 | 2015 | 8515 | 0.170 |
Why?
|
| Ventricular Remodeling | 3 | 2016 | 1256 | 0.170 |
Why?
|
| Neointima | 3 | 2017 | 133 | 0.170 |
Why?
|
| Activities of Daily Living | 5 | 2020 | 2414 | 0.170 |
Why?
|
| Chronic Disease | 11 | 2019 | 9265 | 0.170 |
Why?
|
| Treatment Failure | 6 | 2008 | 2636 | 0.170 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 428 | 0.170 |
Why?
|
| Blood Vessel Prosthesis | 5 | 2016 | 953 | 0.160 |
Why?
|
| Risk | 6 | 2016 | 9590 | 0.160 |
Why?
|
| Plasminogen Activators | 1 | 1999 | 199 | 0.160 |
Why?
|
| Cineangiography | 10 | 2002 | 112 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 2 | 2020 | 412 | 0.160 |
Why?
|
| Erythrocyte Transfusion | 2 | 2020 | 562 | 0.160 |
Why?
|
| Phosphorylcholine | 3 | 2007 | 153 | 0.160 |
Why?
|
| Hypolipidemic Agents | 2 | 2000 | 609 | 0.160 |
Why?
|
| Platelet Aggregation | 2 | 2001 | 773 | 0.160 |
Why?
|
| Miniaturization | 1 | 2018 | 153 | 0.160 |
Why?
|
| Habits | 1 | 2019 | 146 | 0.150 |
Why?
|
| Heart Septum | 1 | 2019 | 303 | 0.150 |
Why?
|
| Coronary Aneurysm | 6 | 2004 | 231 | 0.150 |
Why?
|
| Delirium | 2 | 2020 | 1663 | 0.150 |
Why?
|
| Bayes Theorem | 4 | 2020 | 2320 | 0.150 |
Why?
|
| Iridium Radioisotopes | 5 | 2002 | 26 | 0.150 |
Why?
|
| Aspirin | 12 | 2008 | 3131 | 0.150 |
Why?
|
| ROC Curve | 6 | 2018 | 3562 | 0.140 |
Why?
|
| Heart Ventricles | 3 | 2021 | 3806 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2000 | 391 | 0.140 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2017 | 69 | 0.140 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2019 | 1452 | 0.140 |
Why?
|
| Odds Ratio | 14 | 2018 | 9624 | 0.140 |
Why?
|
| Insurance Benefits | 1 | 2018 | 187 | 0.140 |
Why?
|
| Ventricular Function | 2 | 2018 | 406 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2017 | 1214 | 0.140 |
Why?
|
| Creatine Kinase, MB Form | 5 | 2009 | 202 | 0.130 |
Why?
|
| Dilatation | 1 | 2018 | 307 | 0.130 |
Why?
|
| Patient Care Team | 4 | 2019 | 2504 | 0.130 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2018 | 144 | 0.130 |
Why?
|
| Anesthesia, Local | 1 | 2018 | 276 | 0.130 |
Why?
|
| Endosonography | 5 | 2007 | 607 | 0.130 |
Why?
|
| Chest Pain | 2 | 2003 | 1090 | 0.130 |
Why?
|
| Endothelium, Vascular | 9 | 2007 | 4429 | 0.130 |
Why?
|
| Endocarditis | 2 | 2017 | 349 | 0.130 |
Why?
|
| Cardiovascular Diseases | 12 | 2017 | 15394 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 4 | 2007 | 7401 | 0.130 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2016 | 62 | 0.130 |
Why?
|
| Rubidium Radioisotopes | 3 | 2008 | 76 | 0.130 |
Why?
|
| Arteriosclerosis | 5 | 2003 | 1055 | 0.130 |
Why?
|
| Heart Failure | 4 | 2018 | 11593 | 0.130 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2017 | 352 | 0.130 |
Why?
|
| Tricuspid Valve | 1 | 2018 | 408 | 0.130 |
Why?
|
| Recombinant Proteins | 3 | 2004 | 6525 | 0.130 |
Why?
|
| Data Mining | 1 | 2020 | 551 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 8 | 2004 | 9163 | 0.120 |
Why?
|
| Secondary Prevention | 7 | 2003 | 1474 | 0.120 |
Why?
|
| Vasodilation | 4 | 2008 | 960 | 0.120 |
Why?
|
| Aminophylline | 2 | 2008 | 41 | 0.120 |
Why?
|
| Tantalum | 4 | 2007 | 54 | 0.120 |
Why?
|
| Myocardial Reperfusion | 5 | 2009 | 337 | 0.120 |
Why?
|
| Endarterectomy | 2 | 1992 | 195 | 0.120 |
Why?
|
| Diabetes Complications | 8 | 2006 | 1317 | 0.120 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 878 | 0.110 |
Why?
|
| Comorbidity | 11 | 2018 | 10478 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 20499 | 0.110 |
Why?
|
| Tomography, Optical Coherence | 5 | 2020 | 2880 | 0.110 |
Why?
|
| Survival Analysis | 18 | 2015 | 10075 | 0.110 |
Why?
|
| Safety | 8 | 2007 | 1147 | 0.110 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2018 | 353 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2016 | 1505 | 0.110 |
Why?
|
| Hypotension | 1 | 2019 | 880 | 0.110 |
Why?
|
| Disease-Free Survival | 17 | 2010 | 6808 | 0.110 |
Why?
|
| Intraoperative Complications | 7 | 2018 | 1165 | 0.110 |
Why?
|
| Guideline Adherence | 2 | 2016 | 2212 | 0.110 |
Why?
|
| Pericardium | 1 | 2018 | 674 | 0.110 |
Why?
|
| Vasoactive Intestinal Peptide | 2 | 1990 | 180 | 0.110 |
Why?
|
| Nervous System Diseases | 3 | 2018 | 1647 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2009 | 747 | 0.110 |
Why?
|
| Creatine Kinase | 6 | 2006 | 686 | 0.100 |
Why?
|
| Databases, Factual | 8 | 2020 | 7926 | 0.100 |
Why?
|
| Penile Erection | 1 | 2012 | 100 | 0.100 |
Why?
|
| Retreatment | 7 | 2016 | 596 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 1998 | 960 | 0.100 |
Why?
|
| Ankle Brachial Index | 3 | 2020 | 159 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2152 | 0.100 |
Why?
|
| Drug Therapy, Combination | 6 | 2012 | 6293 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2005 | 3338 | 0.100 |
Why?
|
| Prosthesis-Related Infections | 1 | 2017 | 486 | 0.100 |
Why?
|
| Malnutrition | 1 | 2018 | 639 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2016 | 609 | 0.100 |
Why?
|
| Learning Curve | 1 | 2014 | 229 | 0.100 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2012 | 101 | 0.100 |
Why?
|
| Mammary Arteries | 1 | 1992 | 81 | 0.100 |
Why?
|
| Ultrasonography | 22 | 2005 | 5951 | 0.100 |
Why?
|
| Device Removal | 3 | 2017 | 629 | 0.100 |
Why?
|
| Anesthesia, General | 1 | 2018 | 1165 | 0.100 |
Why?
|
| Blood Pressure | 9 | 2014 | 8452 | 0.090 |
Why?
|
| Limb Salvage | 3 | 2019 | 464 | 0.090 |
Why?
|
| Cardiotonic Agents | 2 | 2008 | 539 | 0.090 |
Why?
|
| Carotid Arteries | 1 | 2015 | 939 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 5 | 2016 | 7366 | 0.090 |
Why?
|
| Probability | 4 | 2007 | 2461 | 0.090 |
Why?
|
| Prognosis | 16 | 2020 | 29493 | 0.090 |
Why?
|
| Research Design | 6 | 2017 | 6151 | 0.090 |
Why?
|
| Proportional Hazards Models | 9 | 2019 | 12400 | 0.090 |
Why?
|
| Chromium | 3 | 2018 | 132 | 0.090 |
Why?
|
| Image Processing, Computer-Assisted | 17 | 2001 | 8945 | 0.090 |
Why?
|
| Adult | 61 | 2018 | 219747 | 0.090 |
Why?
|
| Reproducibility of Results | 14 | 2020 | 20039 | 0.090 |
Why?
|
| Biocompatible Materials | 3 | 2017 | 1688 | 0.090 |
Why?
|
| Ultrasonography, Doppler | 3 | 2021 | 461 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 1991 | 378 | 0.090 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2019 | 1309 | 0.090 |
Why?
|
| Critical Care | 1 | 2003 | 2690 | 0.090 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 14638 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 3 | 2016 | 198 | 0.090 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 809 | 0.090 |
Why?
|
| Fibromuscular Dysplasia | 2 | 2001 | 54 | 0.090 |
Why?
|
| Peptides, Cyclic | 2 | 2005 | 392 | 0.080 |
Why?
|
| Blood Flow Velocity | 9 | 2014 | 1370 | 0.080 |
Why?
|
| Cardiac Pacing, Artificial | 4 | 2018 | 864 | 0.080 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 13603 | 0.080 |
Why?
|
| Drug Delivery Systems | 9 | 2007 | 2211 | 0.080 |
Why?
|
| Pilot Projects | 14 | 2020 | 8551 | 0.080 |
Why?
|
| Aneurysm, False | 4 | 2001 | 254 | 0.080 |
Why?
|
| Lasers, Excimer | 1 | 2009 | 69 | 0.080 |
Why?
|
| Analysis of Variance | 10 | 2008 | 6231 | 0.080 |
Why?
|
| Erectile Dysfunction | 1 | 2012 | 444 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2017 | 1188 | 0.080 |
Why?
|
| Heart Diseases | 3 | 2010 | 2780 | 0.080 |
Why?
|
| Hemorheology | 3 | 2007 | 144 | 0.080 |
Why?
|
| Health Care Surveys | 2 | 2020 | 2426 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 8 | 1997 | 1628 | 0.080 |
Why?
|
| Bluetongue virus | 1 | 2008 | 3 | 0.080 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2009 | 165 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 2 | 2017 | 2455 | 0.080 |
Why?
|
| Heart | 7 | 2008 | 4382 | 0.080 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 1945 | 0.080 |
Why?
|
| Endocardium | 1 | 1989 | 246 | 0.080 |
Why?
|
| Isoenzymes | 5 | 2004 | 1686 | 0.070 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 1991 | 0.070 |
Why?
|
| New Zealand | 4 | 2009 | 352 | 0.070 |
Why?
|
| Cobalt | 2 | 2018 | 154 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2017 | 1908 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1826 | 0.070 |
Why?
|
| Infusions, Intravenous | 7 | 2003 | 2212 | 0.070 |
Why?
|
| Linear Models | 10 | 2018 | 5857 | 0.070 |
Why?
|
| Myocardium | 3 | 2009 | 4690 | 0.070 |
Why?
|
| Acute Kidney Injury | 5 | 2018 | 1923 | 0.070 |
Why?
|
| Observer Variation | 4 | 2015 | 2599 | 0.070 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1992 | 1156 | 0.070 |
Why?
|
| Radiography | 8 | 2015 | 6957 | 0.070 |
Why?
|
| Prostheses and Implants | 3 | 2009 | 1270 | 0.070 |
Why?
|
| Regenerative Medicine | 1 | 2010 | 307 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 2 | 1999 | 875 | 0.070 |
Why?
|
| Patient Readmission | 2 | 2018 | 3241 | 0.070 |
Why?
|
| Hospitals | 2 | 2019 | 3861 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3047 | 0.070 |
Why?
|
| Tomography, Emission-Computed | 3 | 1994 | 1121 | 0.060 |
Why?
|
| Thromboembolism | 2 | 2007 | 995 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 6 | 2018 | 5481 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2018 | 3603 | 0.060 |
Why?
|
| Fluoroscopy | 2 | 2008 | 944 | 0.060 |
Why?
|
| Prevalence | 6 | 2019 | 15641 | 0.060 |
Why?
|
| Subclavian Artery | 2 | 2017 | 134 | 0.060 |
Why?
|
| Educational Technology | 1 | 2005 | 59 | 0.060 |
Why?
|
| Ischemia | 1 | 2014 | 1863 | 0.060 |
Why?
|
| Nanoparticles | 1 | 2017 | 1940 | 0.060 |
Why?
|
| Algorithms | 8 | 2016 | 13952 | 0.060 |
Why?
|
| Balloon Occlusion | 1 | 2006 | 125 | 0.060 |
Why?
|
| Equipment Safety | 5 | 2008 | 249 | 0.060 |
Why?
|
| Government Regulation | 1 | 2009 | 524 | 0.060 |
Why?
|
| Milk | 1 | 2008 | 443 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1605 | 0.060 |
Why?
|
| Heart Function Tests | 2 | 2000 | 318 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 824 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2237 | 0.060 |
Why?
|
| Regression Analysis | 8 | 2001 | 6336 | 0.060 |
Why?
|
| Thrombin | 2 | 2001 | 590 | 0.060 |
Why?
|
| Systems Analysis | 1 | 2005 | 169 | 0.060 |
Why?
|
| Asia | 2 | 2020 | 616 | 0.060 |
Why?
|
| Clinical Competence | 5 | 2012 | 4760 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 2 | 2010 | 1332 | 0.060 |
Why?
|
| Metalloporphyrins | 1 | 2003 | 41 | 0.060 |
Why?
|
| Computer Graphics | 1 | 2005 | 340 | 0.060 |
Why?
|
| Sex Factors | 7 | 2019 | 10497 | 0.060 |
Why?
|
| Vasoconstriction | 2 | 2001 | 592 | 0.060 |
Why?
|
| Vena Cava Filters | 1 | 2006 | 261 | 0.050 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 5105 | 0.050 |
Why?
|
| Hospitalization | 4 | 2019 | 10633 | 0.050 |
Why?
|
| Hematoma | 2 | 2001 | 768 | 0.050 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 3319 | 0.050 |
Why?
|
| Kidney | 1 | 2018 | 7013 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 818 | 0.050 |
Why?
|
| Career Choice | 1 | 2009 | 752 | 0.050 |
Why?
|
| Radial Artery | 1 | 2004 | 184 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 10750 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3579 | 0.050 |
Why?
|
| China | 2 | 2019 | 2336 | 0.050 |
Why?
|
| Professional Review Organizations | 2 | 2012 | 48 | 0.050 |
Why?
|
| Exercise | 1 | 2019 | 5788 | 0.050 |
Why?
|
| Placebos | 3 | 2003 | 1661 | 0.050 |
Why?
|
| Germany | 2 | 2019 | 865 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2003 | 186 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 3984 | 0.050 |
Why?
|
| Delayed-Action Preparations | 5 | 2004 | 961 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2015 | 2847 | 0.050 |
Why?
|
| South America | 1 | 2002 | 180 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2007 | 1658 | 0.050 |
Why?
|
| Ethics, Research | 1 | 2003 | 176 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4760 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 614 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 1598 | 0.050 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 1998 | 239 | 0.050 |
Why?
|
| Pacemaker, Artificial | 2 | 2018 | 808 | 0.050 |
Why?
|
| Age Factors | 7 | 2020 | 18328 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 1501 | 0.050 |
Why?
|
| Hemorrhage | 4 | 2011 | 3399 | 0.050 |
Why?
|
| North America | 2 | 2019 | 1273 | 0.050 |
Why?
|
| Health Care Costs | 3 | 2009 | 3234 | 0.050 |
Why?
|
| Regeneration | 1 | 2010 | 1505 | 0.050 |
Why?
|
| Disease Progression | 6 | 2006 | 13464 | 0.050 |
Why?
|
| Total Quality Management | 2 | 2012 | 264 | 0.050 |
Why?
|
| Hypertension | 1 | 2021 | 8502 | 0.050 |
Why?
|
| Vascular Diseases | 2 | 2011 | 1160 | 0.050 |
Why?
|
| Hospital Costs | 2 | 2018 | 949 | 0.050 |
Why?
|
| Time | 1 | 2002 | 543 | 0.050 |
Why?
|
| Cardiology Service, Hospital | 3 | 2005 | 239 | 0.050 |
Why?
|
| Ioxaglic Acid | 1 | 2000 | 29 | 0.050 |
Why?
|
| Physiology | 1 | 2001 | 111 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2009 | 1128 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3800 | 0.040 |
Why?
|
| Australia | 3 | 2009 | 1235 | 0.040 |
Why?
|
| Echocardiography, Four-Dimensional | 1 | 2020 | 14 | 0.040 |
Why?
|
| Cytochalasin B | 1 | 2000 | 74 | 0.040 |
Why?
|
| Surface Properties | 3 | 2018 | 1159 | 0.040 |
Why?
|
| Videotape Recording | 1 | 2002 | 337 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2000 | 123 | 0.040 |
Why?
|
| Health Care Reform | 1 | 2009 | 1245 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2010 | 2724 | 0.040 |
Why?
|
| Contrast Media | 3 | 2010 | 5297 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 5 | 2012 | 2167 | 0.040 |
Why?
|
| Consensus | 2 | 2021 | 3098 | 0.040 |
Why?
|
| Troponin | 1 | 2003 | 500 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2009 | 3428 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2001 | 271 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 618 | 0.040 |
Why?
|
| Renal Dialysis | 2 | 2018 | 1786 | 0.040 |
Why?
|
| Inpatients | 1 | 2010 | 2536 | 0.040 |
Why?
|
| Arteries | 6 | 2003 | 1125 | 0.040 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1998 | 30 | 0.040 |
Why?
|
| Cholesterol, LDL | 2 | 2005 | 2374 | 0.040 |
Why?
|
| Lung | 1 | 2017 | 9979 | 0.040 |
Why?
|
| Observation | 2 | 2012 | 310 | 0.040 |
Why?
|
| Blood Platelets | 4 | 2001 | 2475 | 0.040 |
Why?
|
| Postoperative Period | 4 | 2016 | 1806 | 0.040 |
Why?
|
| Elasticity | 1 | 2000 | 652 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 4 | 2002 | 222 | 0.040 |
Why?
|
| Netherlands | 3 | 2011 | 2212 | 0.040 |
Why?
|
| Curriculum | 2 | 2010 | 3715 | 0.040 |
Why?
|
| Particle Size | 1 | 2002 | 1641 | 0.040 |
Why?
|
| Antithrombins | 1 | 2001 | 294 | 0.040 |
Why?
|
| Depression | 1 | 2018 | 8052 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2009 | 2767 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 838 | 0.040 |
Why?
|
| Aneurysm | 1 | 2001 | 336 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2008 | 3146 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2000 | 437 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2017 | 47 | 0.040 |
Why?
|
| Oxygen | 1 | 2009 | 4190 | 0.040 |
Why?
|
| Optical Fibers | 1 | 1998 | 135 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2020 | 549 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2001 | 1093 | 0.040 |
Why?
|
| Wounds, Penetrating | 3 | 1994 | 306 | 0.040 |
Why?
|
| Radiation Monitoring | 1 | 1998 | 103 | 0.040 |
Why?
|
| Education, Medical | 1 | 2009 | 1725 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2002 | 756 | 0.040 |
Why?
|
| Peptides | 4 | 2003 | 4340 | 0.040 |
Why?
|
| Normal Distribution | 1 | 2018 | 272 | 0.040 |
Why?
|
| Animals | 15 | 2017 | 167777 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2003 | 819 | 0.030 |
Why?
|
| Health Policy | 1 | 2009 | 2675 | 0.030 |
Why?
|
| Pyridines | 2 | 2004 | 2864 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2004 | 1927 | 0.030 |
Why?
|
| Preoperative Care | 3 | 2019 | 2246 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2008 | 3432 | 0.030 |
Why?
|
| Nitroglycerin | 3 | 1998 | 328 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1998 | 289 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2016 | 1722 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2012 | 3401 | 0.030 |
Why?
|
| Device Approval | 1 | 2018 | 163 | 0.030 |
Why?
|
| Shock | 1 | 2018 | 314 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1406 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 414 | 0.030 |
Why?
|
| Myocardial Contraction | 2 | 1994 | 1516 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 2017 | 203 | 0.030 |
Why?
|
| Benchmarking | 2 | 2012 | 1042 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 2895 | 0.030 |
Why?
|
| Arteriovenous Fistula | 2 | 2001 | 313 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 850 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2017 | 428 | 0.030 |
Why?
|
| Stress, Mechanical | 3 | 2007 | 1664 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 2305 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 2180 | 0.030 |
Why?
|
| Syndrome | 1 | 2001 | 3261 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2019 | 599 | 0.030 |
Why?
|
| Heart Rate | 7 | 2003 | 4166 | 0.030 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 2634 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 384 | 0.030 |
Why?
|
| Light | 1 | 2001 | 1345 | 0.030 |
Why?
|
| Organ Size | 1 | 2020 | 2248 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2018 | 915 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2020 | 891 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2004 | 1795 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1991 | 1486 | 0.030 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 281 | 0.030 |
Why?
|
| Life Tables | 2 | 2005 | 365 | 0.030 |
Why?
|
| Taiwan | 1 | 2015 | 504 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2021 | 1431 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2011 | 5815 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 936 | 0.030 |
Why?
|
| Statistics as Topic | 4 | 2004 | 2357 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 1003 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 1240 | 0.030 |
Why?
|
| Tunica Media | 3 | 1998 | 112 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 2018 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 565 | 0.030 |
Why?
|
| Software | 3 | 2017 | 4416 | 0.030 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2008 | 341 | 0.030 |
Why?
|
| Health Services | 1 | 2018 | 752 | 0.030 |
Why?
|
| Rheology | 2 | 2006 | 348 | 0.030 |
Why?
|
| Health Services Research | 1 | 2020 | 1812 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 1275 | 0.030 |
Why?
|
| Swine | 3 | 2016 | 5892 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2006 | 3220 | 0.030 |
Why?
|
| Elastic Tissue | 2 | 2005 | 65 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2009 | 970 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2009 | 2922 | 0.030 |
Why?
|
| Causality | 2 | 2001 | 1241 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2001 | 1201 | 0.030 |
Why?
|
| Premedication | 2 | 2004 | 247 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 2 | 2012 | 1791 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 12950 | 0.020 |
Why?
|
| Obesity, Morbid | 1 | 2003 | 1276 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2004 | 5098 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 4845 | 0.020 |
Why?
|
| Chromium Compounds | 1 | 2011 | 7 | 0.020 |
Why?
|
| Dopamine | 1 | 1999 | 1599 | 0.020 |
Why?
|
| Creatinine | 2 | 2012 | 1892 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2004 | 2741 | 0.020 |
Why?
|
| Vasodilator Agents | 3 | 2003 | 973 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2016 | 830 | 0.020 |
Why?
|
| Brazil | 2 | 2007 | 1217 | 0.020 |
Why?
|
| Calcium Channel Blockers | 2 | 1991 | 694 | 0.020 |
Why?
|
| Muscle Tonus | 1 | 1990 | 82 | 0.020 |
Why?
|
| San Francisco | 1 | 2011 | 162 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1998 | 1173 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2011 | 94 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2014 | 634 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 1997 | 1294 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2018 | 1607 | 0.020 |
Why?
|
| Warfarin | 1 | 1998 | 1483 | 0.020 |
Why?
|
| Durable Medical Equipment | 1 | 2009 | 23 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2018 | 1295 | 0.020 |
Why?
|
| Hemostasis | 1 | 1992 | 466 | 0.020 |
Why?
|
| Nitrates | 1 | 1991 | 263 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1996 | 831 | 0.020 |
Why?
|
| Insulin | 2 | 2009 | 6578 | 0.020 |
Why?
|
| Education, Medical, Graduate | 2 | 2012 | 2355 | 0.020 |
Why?
|
| Coronary Vasospasm | 1 | 1990 | 81 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2003 | 882 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2009 | 173 | 0.020 |
Why?
|
| Gamma Rays | 2 | 2002 | 317 | 0.020 |
Why?
|
| Social Behavior | 1 | 2015 | 1132 | 0.020 |
Why?
|
| Platinum | 1 | 2010 | 219 | 0.020 |
Why?
|
| Emergencies | 2 | 1992 | 1209 | 0.020 |
Why?
|
| Bluetongue | 1 | 2008 | 3 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2011 | 842 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2782 | 0.020 |
Why?
|
| Cineradiography | 2 | 1998 | 22 | 0.020 |
Why?
|
| Muscle Development | 1 | 2010 | 259 | 0.020 |
Why?
|
| Cholesterol, HDL | 2 | 2005 | 1808 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 1565 | 0.020 |
Why?
|
| Cattle Diseases | 1 | 2008 | 52 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2007 | 3510 | 0.020 |
Why?
|
| Blood Vessels | 1 | 1993 | 1112 | 0.020 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1991 | 478 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 1999 | 2650 | 0.020 |
Why?
|
| Taxus | 1 | 2007 | 2 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2007 | 52 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2008 | 12076 | 0.020 |
Why?
|
| Singapore | 1 | 2008 | 287 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1992 | 1173 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2000 | 3440 | 0.020 |
Why?
|
| Oxygen Consumption | 2 | 1990 | 1846 | 0.020 |
Why?
|
| Calcium | 2 | 1998 | 5722 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 150 | 0.020 |
Why?
|
| Calibration | 1 | 1989 | 813 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 707 | 0.020 |
Why?
|
| Decision Making | 1 | 2000 | 3909 | 0.020 |
Why?
|
| Epoprostenol | 1 | 2007 | 246 | 0.020 |
Why?
|
| Case-Control Studies | 4 | 2009 | 22024 | 0.020 |
Why?
|
| Cell Division | 3 | 1999 | 4459 | 0.020 |
Why?
|
| Capsules | 1 | 2006 | 191 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 1989 | 651 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2001 | 4456 | 0.020 |
Why?
|
| Models, Economic | 1 | 2009 | 715 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2018 | 12870 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2006 | 245 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2000 | 5068 | 0.020 |
Why?
|
| Demography | 2 | 2002 | 1645 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2018 | 3732 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2009 | 679 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1988 | 560 | 0.010 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1991 | 1503 | 0.010 |
Why?
|
| Israel | 1 | 2007 | 721 | 0.010 |
Why?
|
| Smoking | 1 | 2001 | 9036 | 0.010 |
Why?
|
| Cocaine | 1 | 1989 | 958 | 0.010 |
Why?
|
| Erythema | 1 | 1986 | 262 | 0.010 |
Why?
|
| Ethics, Medical | 2 | 2001 | 783 | 0.010 |
Why?
|
| Femoral Vein | 1 | 2004 | 153 | 0.010 |
Why?
|
| Health Facilities | 1 | 2009 | 578 | 0.010 |
Why?
|
| Acute Disease | 3 | 2002 | 7226 | 0.010 |
Why?
|
| Glucagon | 1 | 1986 | 532 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1704 | 0.010 |
Why?
|
| Program Development | 1 | 2010 | 1296 | 0.010 |
Why?
|
| Ethanol | 1 | 1990 | 1324 | 0.010 |
Why?
|
| Models, Animal | 1 | 2010 | 2112 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1436 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 7801 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 2003 | 124 | 0.010 |
Why?
|
| Rest | 1 | 2008 | 914 | 0.010 |
Why?
|
| Belgium | 1 | 2002 | 118 | 0.010 |
Why?
|
| Quebec | 1 | 2002 | 140 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2007 | 1336 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2003 | 272 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1991 | 1470 | 0.010 |
Why?
|
| Walking | 1 | 2009 | 1188 | 0.010 |
Why?
|
| Verapamil | 1 | 2003 | 242 | 0.010 |
Why?
|
| Thrombophilia | 1 | 2005 | 304 | 0.010 |
Why?
|
| Obesity | 1 | 2004 | 12869 | 0.010 |
Why?
|
| Suction | 1 | 2003 | 262 | 0.010 |
Why?
|
| Sodium Chloride | 2 | 1999 | 588 | 0.010 |
Why?
|
| Cattle | 1 | 2008 | 3845 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 2 | 2002 | 2638 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1533 | 0.010 |
Why?
|
| Publishing | 1 | 2009 | 832 | 0.010 |
Why?
|
| Equipment and Supplies | 2 | 1994 | 273 | 0.010 |
Why?
|
| Polysaccharides | 1 | 2008 | 1007 | 0.010 |
Why?
|
| Myocarditis | 1 | 1989 | 765 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16533 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 1373 | 0.010 |
Why?
|
| Adolescent | 4 | 2007 | 87832 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2005 | 4047 | 0.010 |
Why?
|
| Child | 4 | 2012 | 79787 | 0.010 |
Why?
|
| Mental Health | 1 | 2015 | 3231 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2005 | 1632 | 0.010 |
Why?
|
| Massachusetts | 2 | 2005 | 8815 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 2 | 2005 | 2687 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 906 | 0.010 |
Why?
|
| Costs and Cost Analysis | 2 | 1998 | 1667 | 0.010 |
Why?
|
| Radiographic Magnification | 1 | 1998 | 19 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2000 | 642 | 0.010 |
Why?
|
| Phantoms, Imaging | 2 | 1998 | 2509 | 0.010 |
Why?
|
| Problem Solving | 1 | 2001 | 440 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 2370 | 0.010 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2001 | 308 | 0.010 |
Why?
|
| Forecasting | 2 | 1998 | 2919 | 0.010 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 1998 | 141 | 0.010 |
Why?
|
| Pressure | 1 | 2001 | 1154 | 0.010 |
Why?
|
| Body Burden | 1 | 1998 | 158 | 0.010 |
Why?
|
| Professional Competence | 1 | 2001 | 430 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2006 | 4808 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 6371 | 0.010 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2003 | 606 | 0.010 |
Why?
|
| Reference Values | 2 | 1998 | 4918 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2007 | 2685 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2005 | 2490 | 0.010 |
Why?
|
| Hepatovirus | 1 | 1996 | 46 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 3068 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 1996 | 68 | 0.010 |
Why?
|
| Vascular Resistance | 2 | 1990 | 930 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2001 | 2278 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 2082 | 0.010 |
Why?
|
| Quality Control | 1 | 1998 | 825 | 0.010 |
Why?
|
| Cnidaria | 1 | 1995 | 14 | 0.010 |
Why?
|
| Triglycerides | 1 | 2003 | 2450 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 3102 | 0.010 |
Why?
|
| Random Allocation | 2 | 1991 | 2387 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 2875 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 2048 | 0.010 |
Why?
|
| Arousal | 1 | 2001 | 1157 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1995 | 222 | 0.010 |
Why?
|
| Transducers | 1 | 1996 | 240 | 0.010 |
Why?
|
| Exercise Test | 2 | 1994 | 2121 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 4602 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 1989 | 3524 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 3995 | 0.010 |
Why?
|
| Serologic Tests | 1 | 1996 | 384 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1998 | 1485 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 2113 | 0.010 |
Why?
|
| Biliary Tract | 1 | 1995 | 135 | 0.010 |
Why?
|
| Cholesterol, Dietary | 1 | 1994 | 223 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1997 | 662 | 0.010 |
Why?
|
| Compliance | 1 | 1993 | 100 | 0.010 |
Why?
|
| Bile Ducts | 1 | 1995 | 282 | 0.010 |
Why?
|
| Lasers | 1 | 1997 | 951 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 1994 | 557 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 3227 | 0.010 |
Why?
|
| Rotation | 1 | 1994 | 514 | 0.010 |
Why?
|
| Adenosine | 1 | 1997 | 802 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 755 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 6457 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1998 | 1468 | 0.010 |
Why?
|
| Cadaver | 1 | 1995 | 1345 | 0.010 |
Why?
|
| Attention | 1 | 2001 | 2387 | 0.010 |
Why?
|
| Isradipine | 1 | 1990 | 12 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 1992 | 527 | 0.010 |
Why?
|
| Anesthesia | 1 | 2001 | 1581 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1998 | 1957 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1997 | 2770 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1989 | 174 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1996 | 1263 | 0.010 |
Why?
|
| Research | 1 | 1997 | 1975 | 0.010 |
Why?
|
| Heart Block | 1 | 1990 | 392 | 0.010 |
Why?
|
| Dyspnea | 1 | 1997 | 1344 | 0.000 |
Why?
|
| Administration, Intranasal | 1 | 1989 | 471 | 0.000 |
Why?
|
| Injections, Intra-Arterial | 1 | 1987 | 182 | 0.000 |
Why?
|
| Anticholesteremic Agents | 1 | 1994 | 963 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1989 | 837 | 0.000 |
Why?
|
| Lipids | 1 | 1998 | 3326 | 0.000 |
Why?
|
| Pulmonary Circulation | 1 | 1989 | 743 | 0.000 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1991 | 706 | 0.000 |
Why?
|
| Glucagonoma | 1 | 1986 | 14 | 0.000 |
Why?
|
| Acetylcysteine | 1 | 1987 | 261 | 0.000 |
Why?
|
| Sulfhydryl Compounds | 1 | 1987 | 297 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1987 | 367 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 36271 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 1976 | 0.000 |
Why?
|
| Octreotide | 1 | 1986 | 153 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4540 | 0.000 |
Why?
|
| Image Enhancement | 1 | 1993 | 2880 | 0.000 |
Why?
|
| Anesthetics, Local | 1 | 1989 | 998 | 0.000 |
Why?
|
| Life Style | 1 | 1994 | 3886 | 0.000 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 14478 | 0.000 |
Why?
|
| Inflammation | 1 | 2000 | 10718 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1988 | 1804 | 0.000 |
Why?
|
| Diet | 1 | 1988 | 8003 | 0.000 |
Why?
|
| Pancreatic Neoplasms | 1 | 1986 | 5348 | 0.000 |
Why?
|